GlassScriptPhysician profile
Robert H Rifkin
NPI 1639289051
$14,817.54
in general payments reported to CMS, 2019-2025
39 companies · $1,234 in 2025
The $1,234 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,958 · 2020: $801 · 2021: $2,414 · 2022: $2,507 · 2023: $3,227 · 2024: $1,677 · 2025: $1,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,137 · Education: $1.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,136.70 |
| Education | $1.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,217.65 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,792.81 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $1,161.50 | 2019-2022 | |
| Abbvie INC. | $1,104.52 | 2021-2025 | Vraylar |
| Axsome Therapeutics, INC. | $924.96 | 2022-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $752.33 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $666.15 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $651.43 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $646.89 | 2019-2025 | Fanapt |
| Corium, LLC | $553.61 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $463.62 | 2019-2025 | Spravato, Invega Sustenna, Invega |
| Lundbeck LLC | $450.90 | 2019-2023 | Rexulti |
| Bausch Health US, LLC | $447.74 | 2019-2024 | Aplenzin, Wellbutrin |
| Neurocrine Biosciences, INC. | $410.50 | 2019-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $385.71 | 2021-2024 | Qelbree, Qelbree |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rifkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.